Advice
Recommended for restricted use within the NHS in Scotland.
REASONS FOR ADVICE
Treatment with methylphenidate should be part of a comprehensive treatment programme for attention-deficit hyperactivity disorder (ADHD) when remedial measures alone prove insufficient (under specialist supervision). Because of its substantially greater costs, methylphenidate OROS should be restricted to second line therapy and used only in exceptional circumstances where the supervising clinician has clear evidence of compliance problems. As for other methylphenidate preparations, initiation should be on the recommendation of a specialist in childhood behaviour disorders.
Download detailed advice10KB (PDF)
Medicine details
- Medicine name:
- methylphenidate OROS (Concerta)
- SMC ID:
- 04/02
- Indication:
- Attention deficit hyperactivity disorder
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 05 July 2002